How to Test Human CAR T Cells in Solid Tumors, the Next Frontier of CAR T Cell Therapy.

Autor:	Cochrane RW; Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.; Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC, USA.; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA., Fiorentino A; Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.; Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC, USA.; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA., Allen E; Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.; Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC, USA.; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA., Robino RA; Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.; Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC, USA.; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA., Quiroga J; Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.; Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC, USA.; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA., Ferreira LMR; Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA. ferreirl@musc.edu.; Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC, USA. ferreirl@musc.edu.; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA. ferreirl@musc.edu.
Jazyk:	angličtina
Zdroj:	Methods in molecular biology (Clifton, N.J.) [Methods Mol Biol] 2024; Vol. 2748, pp. 243-265.
DOI:	10.1007/978-1-0716-3593-3_16
Abstrakt:	Chimeric antigen receptor (CAR) T cell therapy has proven to be a successful treatment option for leukemias and lymphomas. These encouraging outcomes underscore the potential of adoptive cell therapy for other oncology applications, namely, solid tumors. However, CAR T cells are yet to succeed in treating solid tumors. Unlike liquid tumors, solid tumors create a hostile tumor microenvironment (TME). CAR T cells must traffic to the TME, survive, and retain their function to eradicate the tumor. Nevertheless, there is no universal preclinical model to systematically test candidate CARs and CAR targets for their capacity to infiltrate and eliminate human solid tumors in vivo. Here, we provide a detailed protocol to evaluate human CAR CD4 + helper T cells and CD8 + cytotoxic T cells in immunodeficient (NSG) mice bearing antigen-expressing human solid tumors. (© 2024. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu